Anti-SARS-CoV-2 Antibodies; Neutralizing Antibodies; Omicron; Seroprevalence; Switzerland; Variants of Concern

Seroprevalence of anti-SARS-CoV-2 antibodies and cross-variant neutralization capacity after the Omicron BA.2 wave in Geneva, Switzerland: a population-based study
BACKGROUND: More than two years into the COVID-19 pandemic, most of the population has developed anti-SARS-CoV-2 antibodies from …
Cite